Back
Tarsus Pharmaceuticals, Inc. 10K Form
Sell
41
TARS
Tarsus Pharmaceuticals, Inc.
Last Price:
$77.52
Seasonality Move:
-3.44%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive TARS News And Ratings
See the #1 stock for the next 7 days that we like better than TARS
TARS Financial Statistics
Sales & Book Value
| Annual Sales: | $451.4M |
|---|---|
| Cash Flow: | $13M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $8.07 |
| Price / Book: | 9.36 |
Profitability
| EPS (TTM): | -1.60970 |
|---|---|
| Net Income (TTM): | $-66.4M |
| Gross Margin: | $420.7M |
| Return on Equity: | -21.04% |
| Return on Assets: | -13.42% |
Tarsus Pharmaceuticals, Inc. Earnings Forecast
Key Tarsus Pharmaceuticals, Inc. Financial Ratios
-
The Gross Profit Margin over the past 8 years for TARS is 93.20%.
-
The Selling, General & Administrative Expenses for TARS have been equal to 94.67% of Gross Profit Margin.
-
The Research & Development expenses have been 14.25% of Revenue.
-
The Net Earning history of TARS is -14.72% of Total Revenues.
-
Per Share Earnings over the last 8 years have been positive in 3 years.
Tarsus Pharmaceuticals, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Pharmaceuticals |
| Sector: | Health Care |
| Current Symbol: | TARS |
| Website: | tarsusrx.com |
Debt
| Debt-to-Equity Ratio: | 0.24 |
|---|---|
| Current Ratio: | 3.85 |
| Quick Ratio: | 3.71 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 26.2 |
TARS Technical Analysis vs Fundamental Analysis
Sell
41
Tarsus Pharmaceuticals, Inc. (TARS)
is a Sell
Is Tarsus Pharmaceuticals, Inc. a Buy or a Sell?
-
Tarsus Pharmaceuticals, Inc. stock is rated a SellThe current Tarsus Pharmaceuticals, Inc. [TARS] share price is $75.52. The Score for TARS is 41, which is 18% below its historic median score of 50, and infers higher risk than normal.